News
The FDA has approved the COBAS AmpliPrep/COBAS TaqMan HIV-1 Test, v2.0, a dual-PCR target HIV-1 viral load test from Roche Molecular Diagnostics.The COBAS AmpliPrep/COBAS TaqMan HIV-1 Test, v2.0 ...
Basel, 15 June 2022 – Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today that the US Food and Drug Administration (FDA) issued Emergency Use Authorization (EUA) for the cobas SARS-CoV-2 Duo for ...
INDIANAPOLIS, Nov. 1, 2022 /PRNewswire/ -- Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced plans for the U.S. launch of the cobas® 5800 System, a compact, fully-automated molecular laboratory ...
Roche's dual-target strategy for HIV-1 viral load testing optimizes the quantification of HIV-1 subtypes by simultaneously detecting and amplifying two separate regions of the HIV-1 genome—thus ...
The cobas SARS-CoV-2 Qualitative test is one of the first COVID-19 PCR tests performed on an automated, high throughput platform to receive FDA 510(k) clearance. This FDA clearance will ensure ...
Roche introduces test cobas DPX, a dual test for parvovirus B19 & hepatitis A: Pleasanton, California Tuesday, March 17, 2015, 11:00 Hrs [IST] Roche, a leader in health, focusing on the research ...
Roche: The cobas SARS-CoV-2 Duo test combines the standard qualitative result of a traditional SARS-CoV-2 PCR test with a quantitative result, which measures the viral load of a patient suspected ...
The cobas SARS-CoV-2 Qualitative test is one of the first COVID-19 PCR tests performed on an automated, high throughput platform to receive FDA 510(k) clearance. This FDA clearance will ensure that ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback